Fibulin-5 functions as an endogenous angiogenesis inhibitor

Laboratory Investigation

Volumn 87, Issue 8, 2007, Pages 818-827

  Sullivan, Kaitlyn M ^a   Bissonnette, Rachel ^a   Yanagisawa, Hiromi ^b   Hussain, Sabah N ^c,d   Davis, Elaine C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Angiopoietins; Fibulin 5; Knockout mouse; Vascular sprouting; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; FIBULIN 5; POLYVINYL ALCOHOL; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG IMPLANTATION; ENDOTHELIUM CELL; MAMMARY ARTERY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPROUTING;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; CELL MOVEMENT; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; POLYVINYL ALCOHOL; RECOMBINANT PROTEINS; SKIN; SURGICAL SPONGES; THORACIC ARTERIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447546675     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700594     Document Type: Article

References (53)

1. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-270.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
4. Davis GE, Senger DR. Endothelial extracellular matrix. Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97:1093-1107.
5. Sanz L, Alvarez-Vallina L. The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol Med 2003;9:256-262.
6. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 2004;1654:13-22.
7. Nakamura T, Ruiz-Lozano P, Lindner V, et al. DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. J Biol Chem 1999;274:22476-22483.
8. Kowal RC, Richardson JA, Miano JM, et al. EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature. Circ Res 1999;84:1166-1176.
9. Spencer JA, Hacker SL, Davis EC, et al. Altered vascular remodeling in fibulin-5-deficient mice reveals a role of fibulin-5 in smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 2005;102:2946-2951.
10. Nakamura T, Ruiz-Lozano P, Ikeda Y, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002;415:171-175.
11. Yanagisawa H, Davis EC, Starcher BC, et al. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature 2002;415:168-171.
12. Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004;23:367-379.
13. Albig AR, Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006;66:2621-2629.
14. Lee MJ, Roy NK, Mogford JE, et al. Fibulin-5 promotes wound healing in vivo. J Am Coll Surg 2004;199:403-410.
15. Cox L. Present angiogenesis research and its possible future implementation in wound care. J Wound Care 2003;12:225-228.
16. Zheng Q, Choi J, Rouleau L, et al. Normal wound healing in mice deficient for fibulin-5, an elastin binding protein essential for dermal elastic fiber assembly. J Invest Dermatol 2006;126:2707-2714.
17. Andrade SP, Machado RDP, Teixeira AS, et al. Sponge-induced angiogenesis in mice and the pharmacological reactivity of the neovasculare quantified by a fluorimetric method. Microvasc Res 1997;54:253-261.
18. Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge models. Br J Pharmacol 2000;130:641-649.
19. Andrade SP, Vieira LB, Bakhle YS, et al. Effects of platelet activating factor (PAF) and other vascoconstrictors on a model of angiogenesis in the mouse. Int J Exp Pathol 1992;73:503-513.
20. Bradshaw AD, Reed MJ, Carbon JG, et al. Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Rep Reg 2001;9:522-530.
21. Puolakkainen PA, Bradshaw AD, Brekken RA, et al. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J Histochem Cytochem 2005;53:571-581.
22. Reed MJ, Koike T, Sadoun E, et al. Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. Microvasc Res 2003;65:9-17.
23. Reed MJ, Corsa A, Pendergrass W, et al. Neovascularization in aged mice: delayed angiogenesis is coincident with decreased levels of transforming growth factor beta1 and type I collagen. Am J Pathol 1998;152:113-123.
24. Bradshaw AD, Francki A, Motamed K, et al. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 1999;10:1569-1579.
25. Metheny-Barlow LJ, Li LY. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res 2003;13:309-317.
26. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-471.
27. Brown C, Gaspar J, Pettit A, et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 2004;279:12794-12803.
28. Kadoya K, Sasaki T, Kostka G, et al. Fibulin-5 deposition in human skin: decrease with ageing and ultraviolet B exposure and increase in solar elastosis. Br J Dermatol 2005;153:607-612.
29. Hirai M, Ohbayashi T, Horiguchi M, et al. Fibulin-5/DANCE has an elastogenic organizer activity that is abrogated by proteolytic cleavage in vivo. J Cell Biol 2007;176:1061-1071.
30. Schwarzbauer J. Basement membranes: putting up barriers. Curr Biol 1999;9:R242-R244.
31. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003;22:63-71.
32. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
33. Ren B, Yee KO, Lawler J, et al. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-188.
34. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
35. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-1169.
36. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
37. Peters KG. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 1998;83:342-343.
38. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996;5:35-44.
39. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
40. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-2887.
41. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-1180.
42. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulations of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99: 11205-11210.
43. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1-10.
44. Schiemann WP, Blobe GC, Kalume DE, et al. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. J Biol Chem 2002;277:27367-27377.
45. Lee HJ, Cho C, Hwang S, et al. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J 2004;18:1200-1208.
46. Maharaj ASR, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006;168:639-648.
47. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003;264:275-288.
48. Wakui S, Yokoo K, Muto T, et al. Localization of Ang-1, -2, Tie-2, and VEGF expression at endothelial-pericyte interdigitation in rat angiogenesis. Lab Invest 2006;86:1172-1184.
49. Markova D, Zou Y, Ringfeil F, et al. Genetic heterogeneity of cutis laxa: a heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. Am J Hum Genet 2003;72:998-1004.
50. Loeys B, Van Maldergem L, Mortier G, et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 2002;11:2113-2118.
51. Lotery AJ, Baas D, Ridley C, et al. Reduced secretion of fibulin-5 in agerelated macular degeneration and cutis laxa. Hum Mutat 2006;27:568-574.
52. Stone EM, Braun TA, Russell SR, et al. Missense variations in the fibulin-5 gene and age-related macular degeneration. New Engl J Med 2004;351:346-353.
53. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.